A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Summary

This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study of parsaclisib plus BR versus placebo plus BR as first-line treatment of participants with newly diagnosed MCL.

Timeline

Start

2022-03-11

Primary completion

2030-08-15

Completion

2034-07-07

Outcome

Outcome not reported

Stopped (Enrollment): “business decision; no enrolled patients”

Drugs

Indications